EXPERIMENTAL DESIGN A. Study design This is a supplemental booster vaccine to Protocol 118 (IR# 6304): Phase I -II Study of Combination Immunotherapy for the Generation of HER -2/neu (HER2) Specific Cytotoxic T -Cells (CTL) in vivo. B.